Skip to main content

Table 1 Correlation between CD10 expression and clinicopathological parameters in breast cancer

From: Stromal CD10 expression in breast cancer correlates with tumor invasion and cancer stem cell phenotype

Clinicopathological parameters Total CD10 expression in stromal cells CD10 expression in tumoral cells
n (%) p-value* n (%) p-value*
Age
  < 35 years 18 4 (22.2) 0.33 1 (5.5) 0.87
 35–50 years 63 9 (14.2)   5 (7.9)  
  > 50 years 52 13 (25)   3 (5.7)  
Menopausal status
 Pre- 70 15 (21.4) 0.56 6 (8.5) 0.49
 Post- 63 11 (17.4)   3 (4.7)  
Familial history
 Positive 10 3 (30) 0.11 1 (10) 0.37
 Negative 102 11 (10.7)   4 (3.9)  
Histological gradea
 Grade I 26 0 (0) 0.01 0 (0) 0.03
 Grade II 56 12 (21,4)   1 (1.7)  
 Grade III 51 14 (27.4)   8 (1.5)  
Tumor size
  ≤ 20 mm 43 6 (13.9) 0.26 2 (4.6) 0.5
  > 20 mm 90 20 (2)   7 (7.7)  
Lymph node metastasisb
 No metastasis 46 9 (19.5) 0.01 3 (6.5) 0.9
 1 to 3 lymph nodes 37 3 (8.1)   3 (8.1)  
  > 3 lymph nodes 20 8 (40)   1 (5)  
Visceral metastases
 Positive 10 0 (0) 0.35 0 (0) 1
 Negative 78 14 (17.9)   5 (6.4)  
Estrogen receptorsc
 Positive 62 11 (17.7) 0.62 1 (1.6) 0.002
 Negative 71 15 (21.1)   8 (11.2)  
Progesterone receptorsc
 Positive 65 10 (15.3) 0.23 1 (1.5) 0.001
 Negative 68 16 (23.3)   8 (11.2)  
HER2 statusd
 Positive 32 8 (25) 0.37 3 (9.3) 0.5
 Negative 101 18 (17.8)   6 (5.9)  
  1. aScarff–Bloom and Richardson classification
  2. bThirty patients did not have lymph node resection
  3. cEstrogen and progesterone receptors status was evaluated by immunohistochemistry, and considered positive if ≥1% of tumor cells showed nuclear staining
  4. dEvaluated by immunohistochemistry and considered positive if scored 3+
  5. *Bold number indicates significant p-value